The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

Donepezil

2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.

Trial Locations (15)

Unknown

Seoul National University Bundang Hospital, Bundang

Hallym University Medical Center, Changwon

Kangwon National University Hospital, Chuncheon

Kunkuk University Chungju Hospital, Chungju

Kyungpook National University Hospital, Daegu

Chungnam National University Hospital, Daejeon

Gyeonggi Province Geriatric Hospital, Gyeonggi-do

Uijeongbu St. Mary's Hospital, Gyeonggi-do

Jeju National University Hospital, Jeju City

Jeonju City Welfare Hospital, Jeonju

Gyeongsang National University Hospital, Jinju

Inje University Pusan Paik Hospital, Pusan

Kunkuk University Hospital, Seoul

Seoul National University Hospital, Seoul

Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT00381381 - The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease | Biotech Hunter | Biotech Hunter